OncoMatch/Clinical Trials/NCT06708949
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
Is NCT06708949 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Drugs Nivolumab and Ipilimumab for renal cell carcinoma, clear cell.
Treatment: Drugs Nivolumab · Ipilimumab · BMS-986213 (Relatlimab-Nivolumab FDC) — This is a phase 2 stratified, randomized, multicenter, study investigating the efficacy of a triplet arm treating with nivolumab 480 mg every 4 weeks (Q4W), relatlimab 160 mg Q4W and ipilimumab 1 mg/kg every 8 weeks (Q8W) intravenous (IV) versus a doublet arm treating with nivolumab 480 mg Q3W and ipilimumab 1mg/kg Q3W IV in first-line advanced RCC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Prior therapy
Cannot have received: systemic therapy
Lab requirements
Blood counts
WBC ≥ 2,000 /µL; ANC ≥ 1,500/µL; Platelets ≥ 100,000/µL
Kidney function
Serum creatinine < 1.5 x ULN or creatinine clearance > 30 mL/min (Cockroft-Gault)
Liver function
Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome < 3.0 mg/dL); ALT and AST ≤ 3 x ULN
Cardiac function
Troponin T (TnT) or I (TnI) ≤ 2× ULN (see protocol for repeat testing and exceptions)
Adequate organ function within 28 days prior to first dose... WBC ≥ 2,000 /µL; ANC ≥ 1,500/µL; Platelets ≥ 100,000/µL; Serum creatinine < 1.5 x ULN or creatinine clearance > 30 mL/min; Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome < 3.0 mg/dL); ALT and AST ≤ 3 x ULN; Troponin T (TnT) or I (TnI) ≤ 2× ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Beth Israel Deaconess Medical Center · Boston, Massachusetts
- Duke University Medical Center · Durham, North Carolina
- Vanderbilt University Medical Center · Nashville, Tennessee
- University of Texas Southwestern Medical Center · Dallas, Texas
- The University of Texas M. D. Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06708949 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages